Qiu Yue, Shi Yaqin, Chao Zhujun, Zhu Xinyu, Chen Yan, Lu Linlin
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Ther Adv Med Oncol. 2025 Jan 3;17:17588359241311379. doi: 10.1177/17588359241311379. eCollection 2025.
Despite the availability of multiple treatment options for breast cancer, challenges such as adverse events, drug resistance, and disease progression persist for patients. The identification of human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers, alongside the development of HER2-targeted therapies, has significantly improved the prognosis of HER2-amplified breast cancers. However, therapeutic options remain limited for HER2-overexpressing or HER2-negative breast cancers. In response to this gap, antibody-drug conjugates (ADCs) have emerged as a promising approach. ADCs combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy, which allows for the targeted delivery of a cytotoxic payload to cancer cells. ADCs have been used as adjuvant chemotherapeutic treatments and salvage therapies across various breast cancer subtypes, which have greatly improved the prognosis of breast cancer patients. Numerous ongoing clinical trials seek to optimize dosing strategies and identify patient populations that would benefit most from ADCs. This review presents an updated and comprehensive overview of emerging investigational ADCs for treating breast cancer patients with various HER2 subtypes. These ADCs are spearheading a new era in targeted cancer therapy, promising to innovate treatment paradigms for both HER2-positive and HER2-low breast cancers.
尽管乳腺癌有多种治疗选择，但患者仍面临不良事件、耐药性和疾病进展等挑战。人类表皮生长因子受体2（HER2）被确定为一部分乳腺癌的致癌驱动因素，同时HER2靶向治疗的发展显著改善了HER2扩增型乳腺癌的预后。然而，HER2过表达或HER2阴性乳腺癌的治疗选择仍然有限。针对这一差距，抗体药物偶联物（ADC）已成为一种有前景的方法。ADC将单克隆抗体的特异性与化疗的细胞毒性作用相结合，从而能够将细胞毒性有效载荷靶向递送至癌细胞。ADC已被用作各种乳腺癌亚型的辅助化疗和挽救治疗，极大地改善了乳腺癌患者的预后。众多正在进行的临床试验旨在优化给药策略，并确定最能从ADC中获益的患者群体。本综述对用于治疗各种HER2亚型乳腺癌患者的新兴研究性ADC进行了更新且全面的概述。这些ADC正引领着靶向癌症治疗的新时代，有望为HER2阳性和HER2低表达乳腺癌创新治疗模式。
